Funds and ETFs Cipla Limited

CIPLA

INE059A01026

Name	Weight	AuM	1st Jan change	Investor Rating
WISDOMTREE INDIA EX-STATE-OWNED ENTERPRISES FUND ETF - USD	0.99%	6 M€	+6.07%	-
HARTFORD MULTIFACTOR EMERGING MARKETS ETF - USD	0.44%	18 M€	+3.66%
GOLDMAN SACHS ACTIVEBETA EMERGING MARKETS EQUITY UCITS ETF - ACC - USD	0.28%	11 M€	+1.79%
AMUNDI INDEX MSCI EMERGING MARKETS UCITS ETF DR (D) - EUR	0.12%	441 M€	+4.60%	-
AMUNDI INDEX MSCI EMERGING MARKETS UCITS ETF DR (C) - EUR	0.12%	2,808 M€	+5.90%	-
AMUNDI INDEX MSCI EMERGING MARKETS UCITS ETF - USD	0.12%	149 M€	+2.17%	-
RBC QUANT EMERGING MARKETS EQUITY LEADERS ETF - USD	0.11%	1 M€	+3.49%	-
RBC QUANT EMERGING MARKETS EQUITY LEADERS ETF - CAD	0.11%	3 M€	-.--%	-
SIMPLIFY EMERGING MARKETS PLUS DOWNSIDE CONVEXITY ETF - USD	0.10%	4 M€	-4.41%	-
LEADERSHARES EQUITY SKEW ETF - USD	0.08%	117 M€	+1.11%	-
LEVERAGE SHARES 3X LONG TOTAL WORLD ETP SECURITIES - USD	0.06%	0 M€	0.00%	-
DAY HAGAN/NED DAVIS RESEARCH SMART SECTOR INTERNATIONAL ETF - USD	0.04%	31 M€	+3.50%	-
DEMOCRACY INTERNATIONAL FUND ETF - USD	0.03%	7 M€	+1.95%	-
SPROTT JUNIOR COPPER MINERS ETF - USD	0.03%	7 M€	+26.90%	-
VANGUARD LIFESTRATEGY 80% EQUITY UCITS ETF - DISTRIBUTING - EUR	0.01%	34 M€	+6.71%	-
NOMURA NEXT FUNDS EMERGING MARKET EQUITY MSCI-EM (UNHEDGED) ETF - JPY	0.01%	15 M€	+11.24%
VANGUARD LIFESTRATEGY 80% EQUITY UCITS ETF ACC - EUR	0.01%	389 M€	+6.83%	-
VANGUARD LIFESTRATEGY 60% EQUITY UCITS ETF - DISTRIBUTING - EUR	0.01%	39 M€	+3.67%	-
VANGUARD LIFESTRATEGY 60% EQUITY UCITS ETF - ACC - EUR	0.01%	302 M€	+3.80%	-
UNLIMITED HFND MULTI-STRATEGY RETURN TRACKER ETF - USD	0.01%	34 M€	+2.14%	-
VANGUARD LIFESTRATEGY 40% EQUITY UCITS ETF ACC - EUR	0.01%	108 M€	+2.03%	-
VANGUARD LIFESTRATEGY 40% EQUITY UCITS ETF - DISTRIBUTING - EUR	0.01%	17 M€	+1.44%	-
VANGUARD LIFESTRATEGY 20% EQUITY UCITS ETF ACC - EUR	0.01%	52 M€	-0.60%	-
VANGUARD LIFESTRATEGY 20% EQUITY UCITS ETF - DISTRIBUTING - EUR	0.01%	8 M€	-0.60%	-

Cipla specializes in development, manufacturing and marketing of pharmaceutical products. The group provides prescription products and OTC medicines for the treatment of cardiovascular, ophthalmic and dermatological diseases, respiratory troubles, cancers, allergies, infections etc. Besides, Cipla develops and sells veterinary products. Net sales by source of income break down between sale of products (96.9%) and services (3.1%). Net sales are distributed geographically as follows: India (39.4%), the United States (18.5%), South Africa (17%) and other (25.1%).

Sector

Pharmaceuticals

Calendar

2024-05-09 - Q4 2024 Earnings Release

Related indices

NIFTY 50 , NIFTY 100

More about the company

Income Statement Evolution

More financial data

Ratings for Cipla Limited

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1,409 INR

Average target price

1,453 INR

Spread / Average Target

+3.10%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
CIPLA LIMITED	+13.07%	13.64B
SUN PHARMACEUTICAL INDUSTRIES LTD.	+19.62%	43.34B
OTSUKA HOLDINGS CO., LTD.	+20.44%	21.96B
SANDOZ GROUP AG	+10.86%	14.09B
ZYDUS LIFESCIENCES LIMITED	+37.46%	11.43B
ONO PHARMACEUTICAL CO., LTD.	-8.59%	6.86B
THE MEDICINES COMPANY	-0.05%	6.79B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+8.46%	5.22B
SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.	-4.29%	4.71B

Generic Pharmaceuticals

Market Closed - NSE India S.E. Other stock markets 07:43:47 2024-04-26 am EDT			5-day change	1st Jan Change
1,409 ^INR	+0.21%		+4.71%	+13.07%

Apr. 24	Indian Equities End Higher Midweek as Iran-Israel Conflict Subsides	MT
Apr. 19	Cipla Limited Receives Order from the GST Authority	CI